Organon (OGN) Aperçu de l'action
Organon & Co. développe et fournit des solutions pour la santé des femmes par le biais de traitements sur ordonnance et de dispositifs médicaux aux États-Unis, en Europe, au Canada, au Japon, dans le reste de la région Asie-Pacifique, en Chine, en Amérique latine, au Moyen-Orient, en Russie, en Afrique et dans le reste du monde. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 4/6 |
| Croissance future | 4/6 |
| Performances passées | 0/6 |
| Santé financière | 2/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
OGN Community Fair Values
Create NarrativeSee what 63 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Organon & Co. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$13.74 |
| Plus haut sur 52 semaines | US$13.74 |
| Plus bas sur 52 semaines | US$5.69 |
| Bêta | 1.52 |
| Variation sur 1 mois | 1.70% |
| Variation sur 3 mois | 2.31% |
| Variation sur 1 an | 48.06% |
| Variation sur 3 ans | -36.42% |
| Variation sur 5 ans | -59.54% |
| Évolution depuis l'introduction en bourse | -58.68% |
Nouvelles et mises à jour récentes
Recent updates
Organon & Co: Great Odds, Small Prize, Big Penalty
Summary OGN trades at $13.51 against Sun Pharma's $14.00 all-cash offer, leaving 49 cents for new buyers. The 3.7% spread works out to about 6% annualized if the deal closes in early 2027 as planned. If the deal falls through, expect significant downward pressure, and possible return to pre-announcement lows in single digits. We rate OGN a HOLD. Read the full article on Seeking Alpha
OGN: Takeover Interest And Licensing Pipeline Will Shape Balanced Future Outlook
The analyst fair value estimate for Organon has shifted from $12.00 to $14.00 as analysts factor in updated assumptions on discount rate, revenue growth, profit margins, and potential corporate activity, which are reflected in recent mixed rating changes and takeover commentary. Analyst Commentary Recent research coverage on Organon has been active, with several firms reassessing their views as corporate interest headlines and rating changes come through.
OGN: Takeover Bid And Mixed Ratings Will Likely Cap Share Upside
The analyst price target for Organon stock has been reset lower to $5.00 from $8.00, with analysts pointing to recent mixed rating actions, changing fair value assumptions, and a revised future P/E outlook as key drivers of the update. Analyst Commentary on Organon Stock Recent research on Organon highlights a split in views, with some firms stepping back from formal ratings and others reassessing potential deal scenarios.
OGN: Takeover Bid And Mixed Ratings Will Constrain Future Share Upside
Analysts have kept the fair value estimate for Organon steady at $11.25, while making only minor adjustments to discount rate, profit margin and future P/E assumptions as they digest a mix of recent rating changes and takeover speculation. Analyst Commentary Bullish Takeaways Bullish analysts point to reported takeover interest, including discussion of a possible US$15 per share offer, as a reference point that sits above the current fair value estimate of US$11.25, which they view as supportive for the stock's valuation range.OGN: Deal Premium And Mixed Ratings Will Limit Further Upside Potential
Analysts have lifted their Organon fair value estimate from $9.00 to $11.25, citing updated assumptions for revenue growth, profit margins, discount rate, and future P/E following a mix of recent rating changes, deal interest commentary, and a revised $8.00 price target from Barclays. Analyst Commentary Recent Street research on Organon shows a split view, with some analysts highlighting potential upside drivers and others focusing on execution risks and valuation constraints.OGN: Takeover Talk Will Likely Leave Shares Struggling Below Deal Level
Analysts have nudged Organon’s target higher, reflecting updated models that incorporate recent takeover interest around $15 per share and sector valuation readthroughs, along with revised assumptions for revenue growth, margins, discount rate, and future P/E. Analyst Commentary Recent research highlights a mix of interest and caution around Organon, with potential deal scenarios and updated sector comparisons feeding into valuation work.OGN: Raised Price View Will Likely Leave Shares Trapped Near Lows
Analysts have nudged their Organon price target to $8 from $7.50, reflecting updated models after the latest Q4 report and adjusted assumptions around discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent research reflects a cautious stance around Organon, even as the price target was adjusted to US$8 from US$7.50 after the latest Q4 report.OGN: Cautious Q4 Reassessment Will Likely Keep Shares Anchored Near Lows
Analysts have nudged their price target on Organon up to $8 from $7.50, reflecting updated models after the recent Q4 report and a fresh look at the company’s fundamentals. Analyst Commentary Bearish analysts are treating the latest price target move as a fine tuning of a cautious view rather than a shift in conviction.OGN: Refreshed Earnings Assumptions And M&A Interest Will Support Future Repricing
Analysts have trimmed their fair value estimate for Organon to $9.00, while Barclays lifted its price target to $8.00 from $7.50 after updating its model following the Q4 report, prompting a reassessment of growth, margins and future P/E assumptions in our narrative update. Analyst Commentary Recent Street research reflects a cautious stance on Organon, even as some price targets are adjusted following the Q4 update.OGN: Potential Takeover Interest Will Drive Future Upside Opportunity
Analysts have trimmed their price target on Organon from $18.00 to $12.00, citing updated assumptions that include a revised fair value estimate, a slightly higher discount rate, a modestly adjusted revenue growth outlook, a lower projected profit margin, and a reduced future P/E multiple. What's in the News Organon issued earnings guidance for full year 2026, targeting approximately US$6.2b in revenue, giving investors a reference point for management's current expectations (Corporate guidance).OGN: Acquisition Interest And New Approvals Will Support A Rerated Earnings Profile
Analysts have revised their price targets on Organon. The updated view reflects changes in the discount rate, revenue growth assumptions, profit margin outlook, and future P/E expectations.The Market Lifts Organon & Co. (NYSE:OGN) Shares 25% But It Can Do More
Organon & Co. ( NYSE:OGN ) shares have continued their recent momentum with a 25% gain in the last month alone. Not all...OGN: Governance Reset And Policy Headwinds Will Shape A Steady Execution Path
Narrative update on Organon Analysts have trimmed their price target on Organon to US$9 from US$10, reflecting updated views on U.S. policy headwinds for Nexplanon, recent sales practice issues limited to that product, and softer expectations in the respiratory business that also feed into slightly lower discount rate and future P/E assumptions. Analyst Commentary Recent commentary focuses on how the updated guidance and product specific issues could affect Organon’s valuation, execution risk, and medium term growth profile.OGN: Governance Reset Around Nexplanon Controls Will Gradually Restore Market Confidence
Analysts have trimmed their price targets on Organon, with cuts such as US$10 to US$9 and US$18 to US$5. These changes reflect ongoing concerns about the Nexplanon related investigation, recent leadership changes, and updated revenue guidance.OGN Internal Control Failures Will Likely Drive Shares Toward Mid Single Digits
Analysts have sharply reduced their Organon price target to about $5 from roughly $9, citing downgraded ratings and heightened concerns over internal controls, Nexplanon related channel stuffing, and softer revenue guidance, which is being weighed down by U.S. policy headwinds and respiratory portfolio challenges. Analyst Commentary Bearish analysts are signaling a more cautious stance on Organon, reflecting heightened skepticism around the company’s execution, governance, and growth outlook.OGN: Governance Reset And New Leadership Will Restore Confidence Over Time
Analysts trimmed their price target on Organon by about one dollar to reflect a slightly lower fair value estimate, modestly higher perceived risk, and concerns over internal control breakdowns and Nexplanon-driven revenue headwinds. Analyst Commentary Recent Street research reflects a far more cautious stance on Organon, with reduced price targets and weaker ratings signaling diminished confidence in the company’s near term execution and growth trajectory.OGN: Leadership Changes And Governance Reforms Will Drive Renewed Confidence
Analysts have lowered their price target for Organon and now expect $9.67 per share, compared to the prior estimate of $10.33. The change is attributed to continued headwinds from internal control concerns and weaker revenue growth forecasts.Earnings Release: Here's Why Analysts Cut Their Organon & Co. (NYSE:OGN) Price Target To US$9.67
It's been a pretty great week for Organon & Co. ( NYSE:OGN ) shareholders, with its shares surging 14% to US$7.62 in...OGN: Internal Control Improvements Will Restore Confidence Amid Leadership Transition
Organon’s analyst price target was reduced from $10 to $9, as analysts cited concerns around internal controls, lowered revenue guidance, and lingering effects from recent leadership and business challenges. Analyst Commentary Recent Street research reflects a challenging outlook for Organon, with analysts closely scrutinizing both the company's fundamentals and the longer-term prospects following significant leadership changes and internal control issues.Investors Give Organon & Co. (NYSE:OGN) Shares A 41% Hiding
Organon & Co. ( NYSE:OGN ) shareholders won't be pleased to see that the share price has had a very rough month...Leadership Changes And Regulatory Concerns Will Shape Near-Term Market Prospects
Organon's analyst price target has dropped sharply from $13.17 to $10.83. Analysts cite lingering concerns about internal controls and leadership stability following recent executive changes and investigations.New Product Launches And Biosimilars Will Open Global Healthcare Markets
Despite improved revenue growth forecasts for Organon, a higher discount rate has outweighed these gains, resulting in a lower consensus price target from $13.33 to $12.60. What's in the News Organon raised full-year 2025 revenue guidance to $6.275–$6.375 billion and slightly improved its nominal revenue growth outlook.Why Investors Shouldn't Be Surprised By Organon & Co.'s (NYSE:OGN) 30% Share Price Plunge
To the annoyance of some shareholders, Organon & Co. ( NYSE:OGN ) shares are down a considerable 30% in the last month...Organon's (NYSE:OGN) Dividend Is Being Reduced To $0.02
Organon & Co. ( NYSE:OGN ) is reducing its dividend from last year's comparable payment to $0.02 on the 12th of June...Organon (NYSE:OGN) Use Of Debt Could Be Considered Risky
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Rendement pour les actionnaires
| OGN | US Pharmaceuticals | US Marché | |
|---|---|---|---|
| 7D | 0.1% | 3.4% | -2.1% |
| 1Y | 48.1% | 54.6% | 18.8% |
Rendement vs Industrie: OGN a sous-performé le secteur US Pharmaceuticals qui a rapporté 54.6 % au cours de l'année écoulée.
Rendement vs marché: OGN a dépassé le marché US qui a rapporté 18.8 % au cours de l'année écoulée.
Volatilité des prix
| OGN volatility | |
|---|---|
| OGN Average Weekly Movement | 0.4% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: OGN n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de OGN a diminué de 9% à 0% au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1923 | 10,000 | Joe Morrissey | www.organon.com |
Organon & Co. développe et fournit des solutions de santé féminine par le biais de traitements sur ordonnance et de dispositifs médicaux aux États-Unis, en Europe, au Canada, au Japon, dans le reste de la région Asie-Pacifique, en Chine, en Amérique latine, au Moyen-Orient, en Russie, en Afrique et dans le reste du monde. Le portefeuille de produits de santé féminine de l'entreprise comprend des marques de contraception et de fertilité, telles que Nexplanon, un contraceptif réversible à longue durée d'action, NuvaRing, un anneau contraceptif vaginal mensuel, Cerazette, Marvelon et Mercilon pour prévenir les grossesses ; Follistim AQ, qui est utilisé pour promouvoir le développement des follicules ovariens ; Elonva, un stimulant folliculaire ; Ganirelix acetate injection, un antagoniste injectable ; Jada pour les saignements utérins anormaux post-partum et les hémorragies ; et Xaciato pour la vaginose bactérienne. Son portefeuille de biosimilaires comprend des produits d'immunologie, tels que Brenzys, Renflexis et Hadlima ; des produits d'oncologie, dont Ontruzant et Aybintio ; Bildyos et Bilprevda, des anticorps monoclonaux humains recombinants anti-RANKL ; et Poherdy, un antagoniste des récepteurs du neu.
Organon & Co. Résumé des fondamentaux
| OGN statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$3.61b |
| Bénéfices(TTM) | US$209.00m |
| Recettes(TTM) | US$6.13b |
Le site OGN est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| OGN compte de résultat (TTM) | |
|---|---|
| Recettes | US$6.13b |
| Coût des recettes | US$2.86b |
| Marge brute | US$3.27b |
| Autres dépenses | US$3.06b |
| Les revenus | US$209.00m |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 0.80 |
| Marge brute | 53.40% |
| Marge bénéficiaire nette | 3.41% |
| Ratio dettes/capitaux propres | 850.2% |
Quelles ont été les performances à long terme de OGN?
Voir les performances historiques et les comparaisonsDividendes
Le site OGN verse-t-il des dividendes fiables ?
Voir OGN l'historique des dividendes et les indices de référence| Organon dates des dividendes | |
|---|---|
| Date ex-dividende | Aug 14 2026 |
| Date de paiement du dividende | Sep 10 2026 |
| Jours jusqu'au dividende Ex | 7 days |
| Jours jusqu'à la date de paiement du dividende | 20 days |
Le site OGN verse-t-il des dividendes fiables ?
Voir OGN l'historique des dividendes et les indices de référenceAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/20 04:11 |
| Cours de l'action en fin de journée | 2026/08/20 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Organon & Co. est couverte par 14 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Glen Santangelo | Barclays |
| Navann Ty Dietschi | BNP Paribas |
| Jason Matthew Gerberry | BofA Global Research |